Bioventus Preliminary Q1 2022 Financial Results Show Strong Performance

Bioventus Inc., a leader in innovations for active healing, has shared preliminary financial results for the first quarter ended April 2, 2022.
 
Preliminary, unaudited net sales for the first quarter of 2022 are expected to be in the range of $116.5 million to $118.5 million, reflecting 42% to 45% growth over the prior-year period.
 
“The Bioventus team exhibited strong performance during the first quarter amid a challenging macro environment,” commented Ken Reali, Bioventus’ chief executive officer. “We continued to deliver above-market revenue growth in Pain Treatments and saw monthly sequential improvements in Surgical Solutions revenue growth as elective procedures began to steadily recover in the second half of the quarter.”
 
Preliminary, unaudited net loss and Adjusted EBITDA for the first quarter of 2022 is expected to be in the range of $19.4 million to $19.0 million and $6.8 million to $7.3 million, respectively. Preliminary, unaudited Adjusted EBITDA for the first quarter of 2022 does not reflect the estimated impact on Adjusted EBITDA resulting from the company’s acquisition of CartiHeal, which is expected to close in the second quarter of 2022.
 
These estimated preliminary results for the first quarter of 2022 are derived from the preliminary internal financial records of Bioventus Inc. and are subject to revisions based on procedures and controls associated with the completion of the company’s financial reporting, including the audit of its financial statements and all customary reviews and approvals.